Bayer to buy Teva’s U.S. animal health business

Published on
information-circle This article is more than 3 years old
Bayer HealthCare LLC and Teva Pharmaceutical Industries Ltd. announced Sept. 14 that they have signed an agreement for Bayer to acquire the U.S.-based animal health business of Teva for up to $145 million.

The acquisition will allow Bayer to expand its U.S. product lines for companion and food animals and will allow Teva to focus on human health. The transaction encompasses a manufacturing site in St. Joseph, Mo., and about 300 employees.

Teva’s portfolio in companion animal health includes dermatologic, wellness, and nutraceutical products. Teva’s products for food animals include anti-infectives, parasiticides, anti-inflammatories, and reproductive hormones.